Drug

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
ADC / XDCKelun Pharmaceutical

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that a new indication application for sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) has been accepted for review by the Center for…

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Roche's Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer
CancerOTCMKTS: RHHBY

Roche’s Itovebi Recommended for EU Approval in PIK3CA-Mutated Breast Cancer

rand Pharma's GPN01768 Approved in Macau for Demodectic Blepharitis
Grand PharmaceuticalHKG: 0512

Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis

Zhongsheng Pharma's Anruiwei Receives NMPA Approval for Influenza A
Product approvalsSHE: 002317

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

CARsgen's Satri-Cel Shows Significant Efficacy in Gastric Cancer Study
Academic conferenceCancer

CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study

Show More